Evaluation of the Medicinal Potential of Two Ruthenium(II) Polypyridine Complexes As One- and Two-Photon Photodynamic Therapy Photosensitizers.

Jeannine Hess,Huaiyi Huang,Adrian Kaiser,Vanessa Pierroz,Olivier Blacque,Hui Chao,Gilles Gasser

DOI: https://doi.org/10.1002/chem.201701392

2017-01-01

Chemistry

Abstract:Two [Ru(phen) 2dppz](2+) derivatives (phen= 1,10-phenantroline, dppz= dipyrido[3,2-a: 2', 3'-c] phenazine) with different functional groups on the dppz ligand [dppz-7,8-( OMe)(2) (1), dppz-7,8-(OH)(2) (2)] have been synthesized, characterized and investigated as photosensitizers (PSs) for photodynamic therapy (PDT) against cancer. Both complexes showed intense red phosphorescence and promising singlet oxygen (O-1(2)) quantum yields of 75% (1) and 54% (2) in acetonitrile. Complex 1 (log(Po/w)= -0.52, 2.4 nmol Ru per mg protein) was found to be more lipophilic, having also a higher cellular uptake efficiency compared to 2 (log(Po/ w)= -0.20, 0.9 nmol Ru per mg protein). Complex 1 localized evenly in HeLa cells whereas 2, was mainly visualized in the cell membrane by confocal microscopy. In the dark, complex 1 (IC50= 36.5 mu m) was found to be more toxic than complex 2 (IC50 > 100 mu m) on a HeLa cells monolayer. Importantly, in view of PDT applications, both complexes were found to be non-toxic in the dark towards multicellular HeLa spheroids (IC50> 100 mu m). Upon one-photon irradiation (420 nm, 9.27 Jcm(-2)), 1 exhibited higher phototoxicity (IC50= 3.1 mu m) than 2 (IC50= 16.7 mm) on HeLa cell monolayers. When twophoton irradiation (800 nm, 9.90 Jcm(-2)) was applied, only 1 (IC50= 9.5 mu m) was found to be active toward HeLa spheroids. This study demonstrates that the functional group on the intercalative ligand has a strong influence on the cellular localization and anticancer activity of Ru-II polypyridyl complexes.